摘要
目的观察阿德福韦酯治疗肺结核合并慢性乙型肝炎的临床疗效。方法选择本院2007年3月～2011年3月收治的肺结核合并慢性乙型肝炎患者200例,根据肝功能损害和乙型肝炎病毒定量指标相同的条件,运用匹配原理将患者分为治疗组和对照组,各100例。治疗组应用异烟肼、吡嗪酰胺、利福喷丁、链霉素或乙胺丁醇和传统治疗,同时给予阿德福韦酯10mg口服,每日1次,疗程为8个月。对照组和治疗组一样同时应用抗结核和保肝药物,治疗8个月。比较两组治疗效果、肝功能、病毒载量情况。结果治疗组的肝损伤加重者3例(占6.4%),对照组肝损伤加重18例(占47.3%),差异有统计学意义(P<0.05)。结论阿德福韦酯治疗不存在交叉耐药性,更适用于肺结核合并慢性乙型肝炎患者长期使用,经济实惠、性价比高、安全性好,能够缓解患者的痛苦,促进患者健康,值得临床推广使用。
Objective To observe the effect of Adefovir Dipivoxil （ADV） in treatment of pulmonary tuberculosis com- bined with chronic B hepatitis. Methods Under the same condition of indicatrix on the damage of liver function and quantitative determination of hepatitis B virus, 200 patients treated in our hospital from March 2007 to March 2011 were divided into treatment group and control group by matching principle. The 100 patients in treatment group were treated with Isoniazid, Pyrazinamide, Rifapentine, Streptomycin or Ethambutol and traditional medicine, at the same time, they were given ADV I0 mg/d for 8 months.100 cases in control group were treated with the same anti-tubercu- losis drugs and liver protecting drug as treatment group patients for 8 months. The treatment effect, liver function, viral load of two groups were compared. Results The statistical result of experimental data showed that liver injury worsened in 3 cases of treatment group （accounted for 6.4%）, and 18 cases of control group （accounted for 47.3%）, the difference was statistically significant （P 〈 0.05）. Conclusion ADV treatment has no cross resistance, so it is more suitable for long-term use of the patients with pulmonary tuberculosis combined with chronic B hepatitis. It can relief and elimi- nate the pain of patients, promote the patient＇ s health with economic boon, higher cost-benefit and good safety. So it is worthy of clinical promotion.
出处
《中国当代医药》
2013年第4期61-62,共2页
China Modern Medicine
关键词
肺结核
慢性乙型肝炎
抗病毒药物
肝功能
Pulmonary tuberculosis
Chronic B hepatitis
Antiviral drug
Hepatic function
